查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1600447

抗体治疗市场：按形式、给药途径、来源、疾病领域和最终用户分类 - 全球预测 2025-2030

Antibody Therapeutics Market by Format (Antibody Fragment, Bispecific Antibody, Monoclonal Antibody), Route of Administration (Intravenous, Subcutaneous), Source, Disease Areas, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年抗体治疗市值为2,487.9亿美元，预计到2024年将达到2,857.7亿美元，复合年增长率为14.89%，到2030年将达到6575亿美元。

抗体疗法单株抗体 (mAb) 和其他抗体形式用于治疗癌症、自体免疫疾病和感染疾病等疾病。这些治疗方法的需求是由它们的特异性、有效靶向疾病细胞的能力以及与传统治疗方法相比减少的副作用所驱动的。应用包括肿瘤学、免疫学和病毒学，最终用途扩展到医院、研究机构和专科诊所。推动市场成长的主要因素是生物技术的进步、慢性病发病率的上升以及对研发的大量投资。此外，新型抗体药物的监管核准以及人工智慧的整合以增强药物发现过程是关键的成长动力。双特异性抗体和抗体药物偶联物的开发存在新的商机，它们具有增强的功效和靶向作用。生技公司和研究机构之间的合作也为创新治疗方法铺平了道路。然而，市场限制，例如不断上升的处理成本、复杂的製造流程和监管挑战，可能会减缓成长。小分子和细胞治疗方法等替代疗法也面临激烈的竞争。为了抓住成长机会，企业必须专注于优化供应链并提高生产效率以降低成本。此外，以患者为中心的方法，例如解决罕见疾病中未满足的需求，可以带来差异化。研究应致力于透过个人化医疗缩短开发时间并改善患者的治疗结果。该市场的特点是快速的技术创新和竞争格局，要求企业保持敏捷和适应。持续创新和策略伙伴关係对于在这个充满活力和不断发展的领域中保持成长和保持市场领先至关重要。

主要市场统计
基准年[2023] 2487.9亿美元
预测年份 [2024] 2857.7亿美元
预测年份 [2030] 6575亿美元
复合年增长率（%） 14.89%

市场动态：揭示快速发展的抗体治疗市场的关键市场洞察

供需的动态交互作用正在改变抗体治疗市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 各种癌症和感染疾病的增加
    • 全球药物发现活动的增加
    • 政府努力促进获得抗体治疗
  • 市场限制因素
    • 由于严格的核准指南，抗体治疗药物发生产品召回
  • 市场机会
    • 治疗性抗体临床开发进展
    • 新抗体疗法获得核准的进展
  • 市场挑战
    • 各种治疗方法的疗效不足和副作用

波特五力：引领抗体治疗市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解抗体治疗市场的外部影响

外部宏观环境因素在塑造抗体治疗市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助企业预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解抗体治疗药物市场的竞争状况

对抗体治疗市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵抗体治疗市场供应商的绩效评估

FPNV定位矩阵是评估抗体治疗市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。四个象限清楚且准确地划分供应商，帮助使用者辨识最能满足其策略目标的合作伙伴和解决方案。

本报告提供了涵盖关键重点领域的全面市场分析：

1. 市场渗透率：对当前市场环境的详细回顾，包括行业主要企业的大量资料。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 各种癌症和感染疾病的发生率增加
      • 世界各地的药物发现活动不断增加
      • 政府努力促进获得抗体治疗和疗法
    • 抑制因素
      • 产品召回的发生和抗体疗法的严格核准指南
    • 机会
      • 抗体疗法的临床开发进展
      • 新型抗体疗法和治疗方法的核准正在进行中
    • 任务
      • 各种治疗方法的疗效不足和副作用
  • 市场区隔分析
    • 形式：由于临床使用获得了许多监管部门的核准，单株抗体的使用越来越多。
    • 给药途径：抗体疗法的静脉注射使用正在增加
    • 来源：由于生物相容性，人类抗体的使用增加
    • 疾病领域：感染疾病抗体疗法的使用迅速增加
    • 最终使用者：改进抗体疗法在医院的使用
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章 抗体治疗药物市场格局

  • 抗体片段
  • 双特异性抗体
  • 单株抗体
  • 多株抗体

第七章 抗体治疗药物市场：依给药途径分类

  • 静脉
  • 皮下的

第八章抗体治疗市场：依来源分类

  • 嵌合体
  • 人类
  • 人性化

第九章依疾病领域分類的抗体治疗药物市场

  • 自体免疫疾病与发炎疾病
  • 血液学
  • 免疫学
  • 神经病学
  • 肿瘤学
  • 骨学

第 10 章 抗体治疗市场：依最终使用者分类

  • 医院
  • 长期照护设施

第十一章 北美和南美抗体治疗药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太地区抗体治疗药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章欧洲、中东和非洲的抗体治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • SystImmune 和百时美施贵宝宣布就 BL-B01D1 的开发和商业化达成全球战略合作伙伴协议
    • 艾伯维 (AbbVie) 和 Big Hat Biosciences 宣布开展研究合作，利用人工智慧和机器学习发现下一代治疗抗体
    • 艾伯维（AbbVie）透过收购 Immunogen 扩大固态肿瘤产品组合，包括领先的癌症药物 ELAHERE（mirvetuximab soravitansin-Zinx）
    • MBrace Therapeutics 在 B 系列资金筹措中筹集了 8,500 万美元，以推进创新抗体药物复合体候选物的肿瘤学管道
    • Saripro 与 Icosagen 合作开发单株抗体疗法
    • AbCellera 和 Incyte 合作开发肿瘤治疗抗体
    • 日本授予 BioArctic 帕金森氏症抗体专利
    • 美国FDA核准TALVEY，这是首个双特异性疗法，用于治疗严重治疗的多发性骨髓瘤患者
    • Crossbow Therapeutics 在 A 轮资金筹措中筹集了 8000 万美元，开始开发抗体疗法
    • Crossbow Therapeutics 在 A 轮资金筹措中筹集了 8000 万美元，开始开发抗体疗法
    • Pyxis Oncology 收购抗体治疗公司 Apexigen
    • 默克斥资 108 亿美元收购单株抗体
    • Genmab 和 argenx 合作推进免疫学和肿瘤学领域的抗体疗法

公司名单

  • PharmAbcine Inc.
  • Takeda Pharmaceutical Company Limited
  • AstraZeneca PLC
  • Incyte Corporation
  • Pfizer Inc.
  • MoonLake Immunotherapeutics AG
  • AbbVie Inc.
  • Almac Group Limited
  • Bayer AG
  • Novo Nordisk A/S
  • Genmab A/S
  • Astellas Pharma Inc.
  • Aenova Holding GmbH
  • Argenx SE
  • Thermo Fisher Scientific Inc.
  • Becton, Dickinson and Company
  • AbCellera Biologics Inc.
  • GlaxoSmithKline PLC
  • Biogen Inc.
  • Xencor, Inc.
  • Pyxis Oncology, Inc.
  • Emergent BioSolutions Inc.
  • Antikor Biopharma
  • Evonik Industries AG
  • Sanofi SA
  • Numab Therapeutics AG
  • Merus NV
  • Adaptimmune Therapeutics PLC
  • Merck KGaA
  • Grifols, SA
  • Baxter International Inc.
  • Confo Therapeutics
  • Eli Lilly and Company
  • UCB SA
  • Johnson & Johnson Services, Inc.
  • GE HealthCare Technologies, Inc.,
  • BioNTech SE
  • TRIO Pharmaceuticals Inc.
  • iTeos Therapeutics, Inc.
  • Amgen Inc.
  • MorphoSys AG
  • F. Hoffmann-La Roche Ltd.
  • DotBio Pte. Ltd.
  • Bio-Rad Laboratories, Inc.
  • Bristol-Myers Squibb Company
  • Regeneron Pharmaceuticals, Inc.
  • SAB Biotherapeutics, Inc.
  • DH Life Sciences, LLC
  • ADC Therapeutics SA
  • Novartis AG
Product Code: MRR-A42893A596E8

The Antibody Therapeutics Market was valued at USD 248.79 billion in 2023, expected to reach USD 285.77 billion in 2024, and is projected to grow at a CAGR of 14.89%, to USD 657.50 billion by 2030.

Antibody therapeutics encompasses the use of monoclonal antibodies (mAbs) and other antibody formats to treat diseases, particularly cancers, autoimmune disorders, and infectious diseases. The necessity for these therapies is driven by their specificity, ability to target disease cells effectively, and reduced side effects compared to conventional treatments. They are applied in oncology, immunology, and virology, among others, with end-use extending to hospitals, research institutes, and specialty clinics. Market growth is primarily influenced by advancements in biotechnology, increasing incidence of chronic diseases, and substantial R&D investments. Moreover, regulatory approvals for novel antibody drugs and the integration of AI to enhance the drug discovery process are critical growth drivers. Emerging opportunities lie in the development of bispecific antibodies and antibody-drug conjugates, which offer enhanced efficacy and targeted action. Collaborations between biotech firms and research institutions are also paving the way for innovative therapeutic avenues. However, market limitations include high costs of treatment, complex manufacturing processes, and regulatory challenges, which could retard growth. There is also significant competition from alternative therapies such as small molecules and cell-based treatments. To capitalize on growth opportunities, firms should focus on optimizing supply chains and improving production efficiencies to lower costs. Additionally, patient-centric approaches, such as addressing unmet needs in rare diseases, could provide differentiation. Research should be directed towards shortening the development timeline and improving patient outcomes through personalized medicine. The market is characterized by rapid technological advancements and a competitive landscape, necessitating companies to stay agile and adaptive. Continuous innovation and strategic partnerships are essential for sustaining growth and maintaining market leadership in this dynamic and evolving field.

KEY MARKET STATISTICS
Base Year [2023] USD 248.79 billion
Estimated Year [2024] USD 285.77 billion
Forecast Year [2030] USD 657.50 billion
CAGR (%) 14.89%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Antibody Therapeutics Market

The Antibody Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising incidences of various cancers and infectious diseases
    • Increasing number of drug discovery activities worldwide
    • Government initiatives to promote access to antibody treatments and therapies
  • Market Restraints
    • Incidences of product recalls of antibody therapeutics coupled with strict approval guidelines
  • Market Opportunities
    • Advancements in the clinical development of antibody therapeutics
    • Ongoing approvals for novel antibody therapies and treatments
  • Market Challenges
    • Insufficient efficacy and adverse effects associated with various treatments

Porter's Five Forces: A Strategic Tool for Navigating the Antibody Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Antibody Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Antibody Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Antibody Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Antibody Therapeutics Market

A detailed market share analysis in the Antibody Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Antibody Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Antibody Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Antibody Therapeutics Market, highlighting leading vendors and their innovative profiles. These include PharmAbcine Inc., Takeda Pharmaceutical Company Limited, AstraZeneca PLC, Incyte Corporation, Pfizer Inc., MoonLake Immunotherapeutics AG, AbbVie Inc., Almac Group Limited, Bayer AG, Novo Nordisk A/S, Genmab A/S, Astellas Pharma Inc., Aenova Holding GmbH, Argenx SE, Thermo Fisher Scientific Inc., Becton, Dickinson and Company, AbCellera Biologics Inc., GlaxoSmithKline PLC, Biogen Inc., Xencor, Inc., Pyxis Oncology, Inc., Emergent BioSolutions Inc., Antikor Biopharma, Evonik Industries AG, Sanofi S.A., Numab Therapeutics AG, Merus N.V., Adaptimmune Therapeutics PLC, Merck KGaA, Grifols, S.A., Baxter International Inc., Confo Therapeutics, Eli Lilly and Company, UCB S.A., Johnson & Johnson Services, Inc., GE HealthCare Technologies, Inc.,, BioNTech SE, TRIO Pharmaceuticals Inc., iTeos Therapeutics, Inc., Amgen Inc., MorphoSys AG, F. Hoffmann-La Roche Ltd., DotBio Pte. Ltd., Bio-Rad Laboratories, Inc., Bristol-Myers Squibb Company, Regeneron Pharmaceuticals, Inc., SAB Biotherapeutics, Inc., DH Life Sciences, LLC, ADC Therapeutics SA, and Novartis AG.

Market Segmentation & Coverage

This research report categorizes the Antibody Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Format, market is studied across Antibody Fragment, Bispecific Antibody, Monoclonal Antibody, and Polyclonal Antibody.
  • Based on Route of Administration, market is studied across Intravenous and Subcutaneous.
  • Based on Source, market is studied across Chimeric, Human, and Humanized.
  • Based on Disease Areas, market is studied across Autoimmune & Inflammatory Diseases, Hematology, Immunology, Neurology, Oncology, and Osteology.
  • Based on End User, market is studied across Hospitals and Long-term Care Facilities.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidences of various cancers and infectious diseases
      • 5.1.1.2. Increasing number of drug discovery activities worldwide
      • 5.1.1.3. Government initiatives to promote access to antibody treatments and therapies
    • 5.1.2. Restraints
      • 5.1.2.1. Incidences of product recalls of antibody therapeutics coupled with strict approval guidelines
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in the clinical development of antibody therapeutics
      • 5.1.3.2. Ongoing approvals for novel antibody therapies and treatments
    • 5.1.4. Challenges
      • 5.1.4.1. Insufficient efficacy and adverse effects associated with various treatments
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Format: Significant utilization of monoclonal antibodies due to numerous approvals by regulatory agencies for clinical use
    • 5.2.2. Route of Administration: Growing usage of intravenous administration of antibody therapeutics
    • 5.2.3. Source: Increasing use of human antibodies due to its biocompatible nature
    • 5.2.4. Disease Areas: Proliferating use of antibody therapeutics for infectious diseases
    • 5.2.5. End User: Evolving usage of antibody therapeutics in hospitals
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Antibody Therapeutics Market, by Format

  • 6.1. Introduction
  • 6.2. Antibody Fragment
  • 6.3. Bispecific Antibody
  • 6.4. Monoclonal Antibody
  • 6.5. Polyclonal Antibody

7. Antibody Therapeutics Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Intravenous
  • 7.3. Subcutaneous

8. Antibody Therapeutics Market, by Source

  • 8.1. Introduction
  • 8.2. Chimeric
  • 8.3. Human
  • 8.4. Humanized

9. Antibody Therapeutics Market, by Disease Areas

  • 9.1. Introduction
  • 9.2. Autoimmune & Inflammatory Diseases
  • 9.3. Hematology
  • 9.4. Immunology
  • 9.5. Neurology
  • 9.6. Oncology
  • 9.7. Osteology

10. Antibody Therapeutics Market, by End User

  • 10.1. Introduction
  • 10.2. Hospitals
  • 10.3. Long-term Care Facilities

11. Americas Antibody Therapeutics Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Antibody Therapeutics Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Antibody Therapeutics Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. SystImmune and Bristol Myers Squibb Announce a Global Strategic Collaboration Agreement for the Development and Commercialization of BL-B01D1
    • 14.3.2. AbbVie and BigHat Biosciences Announce Research Collaboration to Leverage Artificial Intelligence and Machine Learning to Discover Next-Generation Therapeutic Antibodies
    • 14.3.3. AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
    • 14.3.4. MBrace Therapeutics Raises USD 85 Million Series B Financing to Advance Oncology Pipeline of Innovative Antibody Drug Conjugate Candidates
    • 14.3.5. Salipro Partners with Icosagen to Develop Monoclonal Antibody Therapies
    • 14.3.6. AbCellera, Incyte Partner on Therapeutic Antibodies in Oncology
    • 14.3.7. Japan Grants Patent for Bioarctic's Parkinson's Disease Antibody
    • 14.3.8. U.S. FDA Approves TALVEY, a First-in-Class Bispecific Therapy for the Treatment of Patients with Heavily Pretreated Multiple Myeloma
    • 14.3.9. Crossbow Therapeutics Debuts with USD 80 Million in Series A Financing to Advance Antibody Therapeutics
    • 14.3.10. Crossbow Therapeutics Debuts with USD 80 Million in Series A Financing to Advance Antibody Therapeutics
    • 14.3.11. Pyxis Oncology to acquire Antibody Therapeutics Company Apexigen
    • 14.3.12. Merck to Develop mAb Through USD 10.8 Billion Acquisition
    • 14.3.13. Genmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and Oncology

Companies Mentioned

  • 1. PharmAbcine Inc.
  • 2. Takeda Pharmaceutical Company Limited
  • 3. AstraZeneca PLC
  • 4. Incyte Corporation
  • 5. Pfizer Inc.
  • 6. MoonLake Immunotherapeutics AG
  • 7. AbbVie Inc.
  • 8. Almac Group Limited
  • 9. Bayer AG
  • 10. Novo Nordisk A/S
  • 11. Genmab A/S
  • 12. Astellas Pharma Inc.
  • 13. Aenova Holding GmbH
  • 14. Argenx SE
  • 15. Thermo Fisher Scientific Inc.
  • 16. Becton, Dickinson and Company
  • 17. AbCellera Biologics Inc.
  • 18. GlaxoSmithKline PLC
  • 19. Biogen Inc.
  • 20. Xencor, Inc.
  • 21. Pyxis Oncology, Inc.
  • 22. Emergent BioSolutions Inc.
  • 23. Antikor Biopharma
  • 24. Evonik Industries AG
  • 25. Sanofi S.A.
  • 26. Numab Therapeutics AG
  • 27. Merus N.V.
  • 28. Adaptimmune Therapeutics PLC
  • 29. Merck KGaA
  • 30. Grifols, S.A.
  • 31. Baxter International Inc.
  • 32. Confo Therapeutics
  • 33. Eli Lilly and Company
  • 34. UCB S.A.
  • 35. Johnson & Johnson Services, Inc.
  • 36. GE HealthCare Technologies, Inc.,
  • 37. BioNTech SE
  • 38. TRIO Pharmaceuticals Inc.
  • 39. iTeos Therapeutics, Inc.
  • 40. Amgen Inc.
  • 41. MorphoSys AG
  • 42. F. Hoffmann-La Roche Ltd.
  • 43. DotBio Pte. Ltd.
  • 44. Bio-Rad Laboratories, Inc.
  • 45. Bristol-Myers Squibb Company
  • 46. Regeneron Pharmaceuticals, Inc.
  • 47. SAB Biotherapeutics, Inc.
  • 48. DH Life Sciences, LLC
  • 49. ADC Therapeutics SA
  • 50. Novartis AG

LIST OF FIGURES

  • FIGURE 1. ANTIBODY THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTIBODY THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. ANTIBODY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. ANTIBODY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTIBODY THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTIBODY THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY FRAGMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY BISPECIFIC ANTIBODY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY POLYCLONAL ANTIBODY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY CHIMERIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HUMAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HUMANIZED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE & INFLAMMATORY DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY OSTEOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY LONG-TERM CARE FACILITIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 238. ANTIBODY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 239. ANTIBODY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023